



(43) International Publication Date 24 December 2003 (24.12.2003)

**PCT** 

## (10) International Publication Number WO 03/105773 A2

(51) International Patent Classification7:

A61K

(21) International Application Number: PCT/US03/18901

(22) International Filing Date: 13 June 2003 (13.06.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/389,107, 13 June 2002 (13.06.2002) US 60/438,899 8 January 2003 (08.01.2003) US

(71) Applicants (for all designated States except US): ORE-GON HEALTH & SCIENCE UNIVERSITY [US/US]; Office of Technology & Research Collaborations, 2525 SW 1st Avenue, Suite #120, Portland, OR 97201 (US). DANA-FARBER CANCER INSITUTE [US/US]; Office of Patent Counsel, 44 Binney Street, Boston, MA 02115 (US). BRIGHAM AND WOMEN'S HOSPITAL [US/US]; Corporated Sponsored Research and Licensing, 75 Francis Street, Boston, MA 02115 (US). THE GOVERNMENT OF THE UNITED STATES d.b.a. THE DEPARTMENT OF VETERANS AFFAIRS [US/US]; Office of the General Counsel, 810 Vermont Avenue N.W., Washington, DC 20420 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HEINRICH, Michael, C. [US/US]; 4649 Winthrop Court, Lake Oswego, OR 97035 (US). CORLESS, Christopher, L. [US/US]; 4904 SW Dosch Park Lane, Portland, OR 97201 (US). FLETCHER, Jonathan, A. [US/US]; 122 Pleasant Street, Apt. 3, Brookline, MA 02246 (US). **DEMETRI**, **George**, **D**. [US/US]; 118 Salisbury Road, Brookline, MA 02445 (US).

- (74) Agent: HARDING, Tanya, M.; Klarquist Sparkman, LLP, One World Trade Center, Suite 1600, 121 SW Salmon Street, Portland, OR 97204 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## **Declaration under Rule 4.17:**

of inventorship (Rule 4.17(iv)) for US only

## Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ACTIVATING MUTATIONS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS:

(57) <u>Abstract:</u> This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions.